Corcept Therapeutics (CORT) Cash from Operations (2016 - 2026)
Corcept Therapeutics (CORT) has disclosed Cash from Operations for 15 consecutive years, with 16772000.0 as the latest value for Q1 2026.
- For Q1 2026, Cash from Operations fell 451.61% year-over-year to 16772000.0; the TTM value through Mar 2026 reached 120454000.0, down 32.82%, while the annual FY2025 figure was 141996000.0, 28.39% down from the prior year.
- Cash from Operations hit 16772000.0 in Q1 2026 for Corcept Therapeutics, down from 38448000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 73293000.0 in Q3 2024 and bottomed at 16772000.0 in Q1 2026.
- Average Cash from Operations over 5 years is 33560176.47, with a median of 35247000.0 recorded in 2022.
- Year-over-year, Cash from Operations skyrocketed 986.24% in 2024 and then crashed 451.61% in 2026.
- Corcept Therapeutics' Cash from Operations stood at 33388000.0 in 2022, then tumbled by 83.44% to 5529000.0 in 2023, then surged by 986.24% to 60058000.0 in 2024, then crashed by 35.98% to 38448000.0 in 2025, then crashed by 143.62% to 16772000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods came in at 16772000.0, 38448000.0, and 54481000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.